Safety and Immunogenicity of Pneumococcal Conjugate Vaccines in a High-risk Population: A Randomized Controlled Trial of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccine in Papua New Guinean Infants
William S Pomat,Anita H J van den Biggelaar,Sandra Wana,Jacinta P Francis,Vela Solomon,Andrew R Greenhill,Rebecca Ford,Tilda Orami,Megan Passey,Peter Jacoby,Lea-Ann Kirkham,Deborah Lehmann,Peter C Richmond,L Bele,M Dreyam,A Elizah,R Ford,J Francis,A Gihigupa,A Greenhill,S Javati,J Kave,W Kirarock,M Lai,B Martin,G Masiria,A Michael,L Moliki,B Nagepu,M Nenikuro,B Nivio,C Opa,T Orami,W S Pomat,G Saleu,P Siba,V Solomon,S Wana,L Wawae,M Yoannes,I Hwaihwanje,T Korowi,C Mond,P Wari,P Jacoby,D Lehmann,A van den Biggelaar,K Corscadden,C de Gier,L Kirkham,T Rahman,P Richmond,R Thornton,M Passey,
DOI: https://doi.org/10.1093/cid/ciy743
IF: 20.999
2018-09-03
Clinical Infectious Diseases
Abstract:BACKGROUND: There are little data on the immunogenicity of PCV10 and PCV13 in the same high-risk population.METHODS: PCV10 and PCV13 were studied head-to-head in a randomized controlled trial in Papua New Guinea in which 262 infants received 3 doses of PCV10 or PCV13 at 1, 2, and 3 months of age. Serotype-specific immunoglobulin G (IgG) concentrations, and pneumococcal and nontypeable Haemophilus influenzae (NTHi) carriage were assessed prevaccination and at 4 and 9 months of age. Infants were followed up for safety until 9 months of age.RESULTS: One month after the third dose of PCV10 or PCV13, ˃80% of infants had IgG concentrations ≥0.35µg/mL for vaccine serotypes, and 6 months postvaccination IgG concentrations ≥0.35 µg/mL were maintained for 8/10 shared PCV serotypes in > 75% of children vaccinated with either PCV10 or PCV13. Children carried a total of 65 different pneumococcal serotypes (plus nonserotypeable). At 4 months of age, 92% (95% confidence interval [CI] 85-96) of children vaccinated with PCV10 and 81% (95% CI 72-88) vaccinated with PCV13 were pneumococcal carriers (P = .023), whereas no differences were seen at 9 months of age, or for NTHi carriage. Both vaccines were well tolerated and not associated with serious adverse events.CONCLUSIONS: Infant vaccination with 3 doses of PCV10 or PCV13 is safe and immunogenic in a highly endemic setting; however, to significantly reduce pneumococcal disease in these settings, PCVs with broader serotype coverage and potency to reduce pneumococcal carriage are needed.CLINICAL TRIALS REGISTRATION: NCT01619462.
immunology,infectious diseases,microbiology